2019 antibiogram now available!

Our 2019 antibiogram, which compiles antimicrobial resistance data from GLA isolates from the calendar year 2019 is now available, posted here.   Overall resistance patterns are largely stable compared to 2018.  Notable findings include: 

For Gram-negative rods in the hospital setting:

Amikacin resistance remains very low and so is still the most active agent vs. multi-drug resistant Gram-negative rod infections at GLA.

Carbapenem-resistant Enterobacteriaceae remain somewhat uncommon at GLA.

If specific coverage for Pseudomonas is warranted, there is not a benefit from using meropenem versus piperacillin-tazobactam (though meropenem and ertapenem do have better coverage against non-Pseudomonas Gram-negative nosocomial isolates. 

Fluoroquinolone susceptibility versus most nosocomial Gram-negative organisms remains poor and ceftriaxone susceptibility among urine nosocomial Gram-negatives is also decreasing. 

Pseudomonas is less frequently encountered in the urine as compared to other sites.

For Gram-negative rods in the outpatient setting:

Cefazolin susceptibility among common urinary Enterobacteriaceae is not readily captured in this antibiogram but susceptibility rates among other beta-lactams remains stable. 

Fluoroquinolone and TMP-SMX susceptibilities remain similar (~75-80%).

Key trends among Gram-positive isolates:

MRSA remains quite common (~70% of nosocomial non-blood isolates, ~60% of nosocomial blood isolates, and ~40% of outpatient isolates).

Doxycycline susceptibility remains stable among non-blood S. aureus isolates (83% nosocomial, 90% outpatient).